An Analysis of HPV Infection and Distribution in Cervical and Genital Samples With Condyloma Acuminatum:A Retrospective Study

Objective:Human papillomavirus(HPV)causes condyloma acuminata,which is one of the most widespread sexually transmitted diseases.This study was aimed to evaluate the prevalence of HPV infection and HPV genotype distribution in patients with condyloma acuminatum in Urumqi,China.Methods:A total of 835 cervical and genital samples were collected from outpatients treated for condyloma acuminatum between December 2016 and December 2018.HPV genotyping was performed with the HPV Genotyping Real-time PCR Kit for 23 different HPV types.Statistcal analysis was conducted using the chi-square test.Results:The total prevalence of HPV infection was 80.72%(674/835)in patients with condyloma acuminatum in Urumqi.The HPV genotypes were HPV-6(372/835,44.55%),HPV-11(180/835,21.56%),HPV-16(91/835,10.90%),HPV-43(65/835,7.78%),HPV-42(56/835,6.71%),and HPV-58(53/835,6.35%).Among HPV-infected individuals,49.11%(331/674)were infected by a single HPV subtype,while 50.89%(343/674)were infected by multiple HPV subtypes.The prevalence of HPV infection was higher in females(82.14%,276/336)than in males(79.76%,398/499)(χ^(2)=0.73,P=0.39),and higher in other ethnicities(86.36%,133/154)than in people of Han ethnicity(79.76%,541/681)(χ^(2)=3.866,P=0.049).The peak prevalence of HPV infection was observed in the age groups of 20-29 years and 30-39 years.Conclusion:HPV infection was detected in most patients with condyloma acuminatum in Urumqi with prevalence of 80.72%,and the most common HPV types were HPV-6,-11,-16,-43,-42,and-58.The detection of HPV genotypes is very important to monitor HPV infection so that effective treatment is administered to patients with condyloma acuminatum.

Effectiveness and safety of different doses of pioglitazone in psoriasis:a meta-analysis of randomized controlled trials

Background:Pioglitazone may be beneficial in the treatment of psoriasis.However,based on the effectiveness and safety considerations,it has not been widely used.To fully evaluate the strength of evidence supporting psoriasis treatment with pioglitazone,we conducted a meta-analysis of existing published studies.Methods:PubMed,Ovid,Cochrane Library,Google Scholar,and Web of Science databases were systematically searched before February 2019.Randomized controlled trials(RCTs)of pioglitazone administration compared with placebo,administered to patients with psoriasis for at least 10 weeks,and published in English were included.Quality of the included RCTs was identified by the modified Jadad scale.The quality of evidence for each outcome was evaluated using the GRADEpro Guideline Development Tool online software.Primary outcomes were proportion of patients showing psoriasis area and severity index(PASI)score improvement(<75%)and the mean percent change in PASI score from baseline to the end of treatment.Dichotomous data were analyzed using odds ratios(ORs)corresponding to the 95%confidence interval(CI),whereas continuous variables,expressed as mean and standard deviation,were analyzed using the mean differences(MD)with the 95%CI.Results:Six RCTs were analyzed.Meta-analysis showed that pioglitazone reduced the PASI scores in patients with psoriasis compared with the control group when administered at 30 mg per day(P<0.001,MD=-3.82,95%CI=-5.70,-1.93)and at 15 mg per day(P=0.04,MD=-3.53,95%CI=-6.86,-0.20).The PASI-75 of the pioglitazone group was significantly higher than that of the control group at 30 mg per day(P<0.001,OR=8.30,95%CI=3.99,17.27)and at 15 mg per day(P=0.03,OR=2.96,95%CI=1.08,8.06).No statistically significant differences in total adverse events were observed between the groups.There were no significant differences in common adverse reactions such as weight gain and elevated liver enzymes between the two pioglitazone groups.Conclusions:Use of pioglitazone in the current treatment of psoriasis is beneficial.The therapeutic effect of the daily 30 mg dose may be greater than that of the 15 mg dose per day with no significant change in the frequency of adverse reactions.